SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Seattle, Washington, USA downtown skyline in the afternoon
Job Trends
Washington’s life sciences jobs continue increasing, up 50% from 2014-2024: report
While life sciences employment was down 0.3% nationally in 2024, it rose 1.9% in Washington, according to a new Life Science Washington report. The association’s CEO discusses the latest findings and how the state’s job market looks this year.
April 23, 2026
 · 
3 min read
 · 
Angela Gabriel
3D Yellow triangle warning sign symbol on yellow background. Emergency alert, and caution. Illustration with copy space
Manufacturing
FDA issues warning letter after GLP-1 manufacturer refuses inspectors access
New Life told FDA inspectors that they lacked the authority to enter parts of a facility where it made the GLP-1 receptor agonists semaglutide and tirzepatide.
April 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Hypnotherapy session, subconscious research. Psychiatrist assistance. Hypnosis practice, altered state of mind, hypnosis treatment services concept. Header or footer banner template with copy space.
Psychedelics
Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients
With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead for psychedelics. But will sidestepping normal regulatory protocols actually be a net negative for the field?
April 22, 2026
 · 
8 min read
 · 
Heather McKenzie
Illustration of businessman confused about choosing from multiple signposts
Leadership
The 4 biggest hiring mistakes biopharma executives keep making
Finding the right people for critical open roles can be difficult even for biopharma leaders. In this column, Kaye/Bassman’s Michael Pietrack discusses four pitfalls executives face during the hiring process, starting with confusing scientific brilliance with leadership ability.
April 22, 2026
 · 
5 min read
 · 
Michael Pietrack
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
rare diseases
Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision
The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and overall data.
April 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor
stock pile of used auto parts store for sale recycle, car old wheel hub spare part from scrapyard
Business
Lilly exits Rigel alliance, adding to RIPK1 scrap heap
Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous system indications.
April 22, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win
The deals keep rolling in, with Lilly penning a $7 billion pact for gene delivery biotech Kelonia Therapeutics and UCB taking over cell therapy-focused Neurona Therapeutics; President Trump signed a new executive order supporting the development of psychedelic therapies, sparking fanfare and concern alike; and the FDA’s recent Replimune decision has triggered broader debate about the agency’s flexibility.
April 22, 2026
 · 
1 min read
 · 
Heather McKenzie
Wooden blocks with arrow and error icon. Delays and disruptions, stop the process, critical error concept
GLP-1
Lilly, Novo dip as proposed Medicare coverage for GLP-1 pilot thrown off balance
Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients.
April 22, 2026
 · 
2 min read
 · 
Tristan Manalac
Thumb up close-up in surgical, medical gloves, gesture, recommendation for a successful operation. Pink background.
Regulatory
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot
In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for resubmission remains uncertain.
April 22, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS